REPORT DOCUMENTATION PAGE

17. SECURITY CLASSIFICATION

Unclassified

OF REPORT

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND I	DATES COVERED
•	15 January 1999	Final 1 Octob	er 1997-30 September 1998
4. TITLE AND SUBTITLE Children's Hospital of Pi Molecular Typing of Allel Loci on Blood Spotted Fil 6. AUTHOR(S) Massimo Trucco, M.D.	es at HLA Class I an		5. FUNDING NUMBERS N00014-97-1-1060
7. PERFORMING ORGANIZATION NAMES(S)	AND ADDRESS(ES)		8. PERFORMING ORGANIZATION
Children's Hospital of Rangos Research Center 3460 Fifth Avenue Pittsburgh, PA 15213-3	Pittsburgh		REPORT NUMBER 335
9. SPONSORING / MONITORING AGENCY NA	MES(S) AND ADDRESS(ES)		10. SPONSORING / MONITORING
Department of the Navy Office of Naval Researc 800 North Quincy Street Arlington, VA 22217-56		10	990120 105
11. SUPPLEMENTARY NOTES		17	
a. DISTRIBUTION / AVAILABILITY STATEMEN	NT		12. DISTRIBUTION CODE
Approved for Public Rel	ease; distribution i	s Unlimited.	•
13. ABSTRACT (Maximum 200 words)			
three major categories: 1) the activities aimed at improving This year in the Repository, we from more than 120 recruitin 450,000 vials were stored in 130,000 were sent out to o typings were performed with Program. Our Center's reseas or labelled probes to perform hybridization results were not filter paper) or for enhance	the repository service; 2) the general support or where blood samples from g centers nationwide, rough three sets of freezers (on ther Typing Laboratorie havery high Q.C. stand rech branch synthesized all m molecular HLA typing of optimal. Alternatives ing typing capabilities (ne molecular typing which the previous volunteers as bonghly 150,000 sample sample per dones. In our laboral ard, as monitored the oligonucleotic, DNA sequencifor storing blood e.g., microchip to	Center can be classified under a service; and 3) the research ous two services are working. The marrow donors are collected ples were processed. Close to or each freezer), while nearly tories, approximately 10,000 d by National Marrow Donor des to be used as PCR primers and was also performed when samples (e.g., blood spots on technology to expedite PCR int of justifying their future
14. SUBJECT TERMS			15. NUMBER OF PAGES
			7 16. PRICE CODE

18. SECURITY CLASSIFICATION

Unclassified

OF THIS PAGE

UL Standard Form 298 (Hev. 2-89) Prescribed by ANISE Sad Z39-16 296-102

19. SECURITY CLASSIFICATION

Unclassified

OF ABSTRACT

20. LIMITATION OF ABSTRACT

CHILDREN'S HOSPITAL OF PITTSBURGH HISTOCOMPATIBILITY CENTER

AWARD NUMBER: N00014-97-1-1060

Total Samples Typed and Results Sent from 10/01/97 to 09/30/98

	Total	Priority 1	Priority 2	Priority 3	No Makes	Navy
1997				-		
October	1013	119	894	0	0	0
November	851	161	690	0	0	0
December	822	122	700	0	3	0
1998						
January	838	130	708	0	Ö	0
February	854	263	591	0	1	0
March	1029	348	681	0	2	0
April	820	174	646	0	0	0
May	976	116	860	0	0	0
June	865	300	565	0	0	0
July	805	49	756	0	0	0
August	818	159	659	0	0	0
September	1026	188	838	0	0	0

CHILDREN'S HOSPITAL OF PITTSBURGH HISTOCOMPATIBILITY CENTER

AWARD NUMBER: N00014-97-1-1060

Total Samples Received, Stored and Shipped from the Repository from 10/01/97 to 09/30/98

SAMPLES	NUMBER	NUMBER	NUMBER
	(October1997)	(November 1997)	(December 1997)
Stored	11,593	13,743	12,523
Shipped (AB - Class I)	4,700	5,800	7,400
Shipped (DR - Class II)	9,394	6,614	8,463
Not stored	87	113	149
Destroyed	0	238	0
SAMPLES	NUMBER	NUMBER	NUMBER
SAMPLES	NUMBER (January '98)	NUMBER (February '98)	NUMBER (March '98)
SAMPLES			
	(January '98)	(February '98)	(March '98)
Stored	(January '98) 8,192	(February '98) 7,437	(March '98) 16,264
Stored Shipped (AB - Class I)	(January '98) 8,192 3,400	(February '98) 7,437 4,300	(March '98) 16,264 5,100

SAMPLES	NUMBER	NUMBER	NUMBER
	(April '98)	(May '98)	(June '98)
Stored	14,769	14,028	11,628
Shipped (AB - Class I)	5,250	4,100	5,700
Shipped (DR - Class II)	4,862	4,580	4,140
Not stored	173	99	98
Destroyed	464	0	1,131
			I
SAMPLES	NUMBER	NUMBER	NUMBER
	(July '98)	(August '98)	(September '98)
Stored	11,709	10,703	10,601
Shipped (AB - Class I)	5,100	4,300	3,175
Shipped (DR - Class II)	4,031	4,668	5,115
1		1	
Not stored	101	143	59

- <u>Stored samples</u> (Multiply number stored x 3 because of triplicate aliquots)
- <u>Shipped samples</u> (Separated by AB and DR samples)
- <u>Not Stored</u> because of insufficient quantity; duplicate tubes; too clotted; broken; wrong anti-coagulant.
- <u>Destroyed</u> because no longer eligible, so that blood sample must be removed from NMDP list.

CHILDREN'S HOSPITAL OF PITTSBURGH HISTOCOMPATIBILITY CENTER

AWARD NUMBER: N00014-97-1-1060

Research Completed from 10/01/97 to 09/30/98

Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	Visible Genetics Sequencing:	Research Projects:
Oct '97	31	163 reactions	0*	Began exploring optimal PCR conditions for both HLA-A and HLA-B typing using Visible Genetics Microblaster Sequencer. Continued to expand cell reference lines for cell and DNA bank. Synthesized 1 Taqman Probe.
Nov '97	26	42 reactions	0*	New Rhodamine terminator chemistry validated on sequencer. Rhodamine matrix installed on sequencer. Installation of Visible Genetics Sequencer. Class 1 HLA-A and HLA-B PCR amplification optimized for sequencing conditions.
Dec '97	16	104	14	Performed control samples for Class 1 typing on Visible Genetics sequencer. Continued to optimize amplifications and cycle sequencing for HLA-A and HLA-B.
Jan '98	24	94	5	Began training personnel on Visible Genetics Sequencer for Class 1 typing. Performed a quality control study for Visible Genetics sequencer using 3 unknown typing samples and 3 known typing samples.

Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	Visible Genetics Sequencing:	Research Projects:
Feb '98	62	65	11	Set up data base for Visible Genetics Class 1 typing.
				Continued validation of Class 1 typing via sequencing.
				Troubleshooting on Class 1 typing reactions using Visible Genetics sequencer.
Mar '98	31	130	7	Big Dye terminator chemistry validated and installed on sequencer.
				Optimized cycle sequencing for Big Dye Terminator Kit.
	,			Expanded cell line references.
				Continued troubleshooting on Class 1 typing reactions using Visible Genetics sequencer.
Apr '98	26	88	2	Continued to optimized cycle sequencing for Big Dye Terminator Kit.
				Evaluated and optimized PCR "clean- up" methods for new sequencing chemistry.
				Continued to expanded cell line references.
May '98	19	117	3	Installed and updated Visible Genetics sequencer: OpenStep 3.0 software.
				Synthesized 3 Taqman Probes.
				Began evaluating DNA sequencing systems using capillary electrophoresis on a computer chip.
				Continued to expanded cell line references.

Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	Visible Genetics Sequencing:	Research Projects:
Jun '98	43	89	11	Evaluated sequencing methods for chip technology.
			:	Developed chip design for DNA sequencing.
				Initiated orders for chip sequencing.
				Installed Iomega "Jazz" System tape back-up for the hard drive on the Visible Genetics Sequencer.
				Synthesized 1 Taqman Probe.
				Continued to expanded cell line references.
	,			
Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	CE Sequencing**:	Research Projects:
July '98	41	124	12	Began instrumental set-up for DNA sequencing via capillary electrophoresis (CE) - computer chip technology.
				Optimized PCR for CE sequencing
Aug '98	28	86	18	Explored polymers and began initial testing.
				Continued instrumental set-up for CE chip sequencing runs.
				Continued optimizing PCR conditions for CE runs.
Sep '98	22	125	10	Continued optimizing PCR conditions for CE runs.
				Continued to evaluate polymers for CE sequencing.
				Began literature search on new HPLC techniques for DNA purification.

^{*} Visible Genetics sequencing instrument was not yet purchased at this time.

^{**} Instituted new project utilizing capillary electrophoresis (CE) for DNA sequencing in July 1998.